PrimeRFP SCOUT · Federal Contract Recompete Brief

HHSO100201700016CEBOLA therapeutics — Regeneron Pharmaceuticals, Inc

Regeneron Pharmaceuticals, Inc holds $-7,005,694 across 6 federal awards. Competition previously drew 2 offers. Set-aside status: NONE. Recompete timing centers on the Sep 29, 2027 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Regeneron Pharmaceuticals, Inc

Recipient

Sep 29, 2027

PoP end

$2.7M

Obligated

541711

NAICS

AN13

PSC

NONE

Set-aside

2 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Regeneron Pharmaceuticals, Inc — $90

Contract facts

NONE

Contract numberHHSO100201700016C

AgencyBarda - Aspr / Daappo / Barda Dcma

Awarding officeBarda - Aspr / Daappo / Barda Dcma

IncumbentRegeneron Pharmaceuticals, Inc

UEIN3F9MH7E6HD6

NAICS541711

No full NAICS 541711 intel page yet. Browse NAICS intelligence

PSCAN13

Place of performanceTARRYTOWN, NY

Related solicitation17100SOL00014

PoP end (current)Sep 29, 2027

Obligated$2.7M

EBOLA THERAPEUTICS is a federal NONE award for Barda - Aspr / Daappo / Barda Dcma held by Regeneron Pharmaceuticals, Inc. Estimated value $695.7M ($2.7M obligated). Current period of performance ends Sep 29, 2027. Last award drew 2 bidders. Place of performance: TARRYTOWN, NY. Related solicitation 17100SOL00014.

Recompete timing

Public

● Expiring in 388 days

Current PoP ends Sep 29, 2027 (388 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.

Incumbent footprint

Public record

Regeneron Pharmaceuticals, Inc — $-7,005,694 obligated across 6 awards (firm-wide, all agencies).

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract HHSO100201700016C?

HHSO100201700016C (EBOLA therapeutics) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $695.7M, currently held by Regeneron Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded HHSO100201700016C?

Barda - Aspr / Daappo / Barda Dcma awarded HHSO100201700016C to Regeneron Pharmaceuticals, Inc.

Who is the incumbent on HHSO100201700016C?

Regeneron Pharmaceuticals, Inc is the incumbent with $-7,005,694 across 6 related awards in SCOUT’s public footprint. The current period of performance ends Sep 29, 2027.

When does Regeneron Pharmaceuticals, Inc’s HHSO100201700016C come up for recompete?

SCOUT tracks a period-of-performance end of Sep 29, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on HHSO100201700016C — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Jul 30, 2026